Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (15027)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Mar 18, 2016 (publication date) through Nov 29, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Bessone F, Dirchwolf M. Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations. World J Hepatol 2016; 8(8): 385-394 [PMID: 27004086 DOI: 10.4254/wjh.v8.i8.385] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v8/i8/385.htm |
| Number | Citing Articles |
| 1 |
Jie Wang, Junqiao Jia, Ran Chen, Shanlong Ding, Qiang Xu, Ting Zhang, Xiangmei Chen, Shuang Liu, Fengmin Lu. RFX1 participates in doxorubicin‐induced hepatitis B virus reactivation. Cancer Medicine 2018; 7(5): 2021 doi: 10.1002/cam4.1468
|
| 2 |
Tsofia Inbar, Shehrban Sobeh Khalil, Ron Ram, Chezi Ganzel, Yishai Ofran. Low risk for viral reactivation during induction for acute myeloid leukemia in patients with resolved hepatitis B infection. Leukemia & Lymphoma 2020; 61(5): 1260 doi: 10.1080/10428194.2019.1702187
|
| 3 |
Alexandr Zinchuk, Oleksandr Herasun, Andrij Zadorozhnyi, Olga Vorozhbyt, Borys Gerasun. INFLUENCE OF AUTOLEUKOCYTE VACCINATION ON ACTIVITY LEVEL OF TUMOR NECROSIS FACTOR ALPHA IN PATIENTS WITH CHRONIC HEPATITIS B. Wiadomości Lekarskie 2019; 72(1): 31 doi: 10.36740/WLek201901106
|
| 4 |
Marco Fiore, Sebastiano Leone, Alberto Enrico Maraolo, Emilio Berti, Giovanni Damiani. Liver Illness and Psoriatic Patients. BioMed Research International 2018; 2018: 1 doi: 10.1155/2018/3140983
|
| 5 |
Jason T. Blackard, Kenneth E. Sherman. Hepatitis B virus (HBV) reactivation—The potential role of direct‐acting agents for hepatitis C virus (HCV). Reviews in Medical Virology 2018; 28(4) doi: 10.1002/rmv.1984
|
| 6 |
Yu-tuan Wu, Xin Li, Zi-li Liu, Zhou Xu, Wei Dai, Ke Zhang, Jiu-song Wu, Bilal Arshad, Kai-nan Wu, Ling-quan Kong, Chiaho Shih. Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis. PLOS ONE 2017; 12(6): e0179680 doi: 10.1371/journal.pone.0179680
|
| 7 |
Ioanna Aggeletopoulou, Christos Konstantakis, Spilios Manolakopoulos, Christos Triantos. Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C. World Journal of Gastroenterology 2017; 23(24): 4317-4323 doi: 10.3748/wjg.v23.i24.4317
|
| 8 |
Eileen L. Yoon, Hyung Joon Yim. Updated Treatment of Chronic Hepatitis B. The Korean Journal of Medicine 2019; 94(3): 252 doi: 10.3904/kjm.2019.94.3.252
|
| 9 |
Maria Guarino, Marco Picardi, Anna Vitiello, Novella Pugliese, Matilde Rea, Valentina Cossiga, Fabrizio Pane, Nicola Caporaso, Filomena Morisco. Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma. Annals of Hepatology 2017; 16(2): 198 doi: 10.5604/16652681.1231579
|
| 10 |
Jacinta A. Holmes, Ming-Lung Yu, Raymond T. Chung. Hepatitis B reactivation during or after direct acting antiviral therapy – implication for susceptible individuals. Expert Opinion on Drug Safety 2017; 16(6): 651 doi: 10.1080/14740338.2017.1325869
|
| 11 |
Romina Salpini, Arianna Battisti, Luna Colagrossi, Domenico Di Carlo, Lavinia Fabeni, Lorenzo Piermatteo, Carlotta Cerva, Miriam Lichtner, Claudio Mastroianni, Massimo Marignani, Sarah Maylin, Constance Delaugerre, Filomena Morisco, Nicola Coppola, Aldo Marrone, Mario Angelico, Loredana Sarmati, Massimo Andreoni, Carlo‐Federico Perno, Francesca Ceccherini‐Silberstein, Valentina Svicher. A snapshot of virological presentation and outcome of immunosuppression‐driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection. Journal of Viral Hepatitis 2019; 26(7): 846 doi: 10.1111/jvh.13101
|
| 12 |
Rafael Mican, Carmen Busca Arenzana, Julia Vasquez, German Daroca, Ignacio Perez-Valero, Luz Martin-Carbonero. Hepatitis B reactivation after tenofovir withdrawal in an HIV-infected patient with history of cured hepatitis B virus infection and poor immunological status. AIDS 2021; 35(10): 1707 doi: 10.1097/QAD.0000000000002941
|
| 13 |
Takako Inoue, Takeshi Matsui, Yasuhito Tanaka. Novel strategies for the early diagnosis of hepatitis B virus reactivation. Hepatology Research 2021; 51(10): 1033 doi: 10.1111/hepr.13699
|
| 14 |
Shih-Yu Yang, Tsung-Hui Hu, Yeh-Pin Chou, Yuan-Hung Kuo, Ming-Chao Tsai, Kuo-Chin Chang, Yi-Hao Yen, Po-Lin Tseng. Long-term comparisons of the durability of 6 months versus 12 months antiviral therapy for hepatitis B after chemotherapy cessation. Journal of Infection and Public Health 2023; 16(11): 1852 doi: 10.1016/j.jiph.2023.08.006
|
| 15 |
Anil Arora, Anil C. Anand, Ashish Kumar, Shivaram P. Singh, Rakesh Aggarwal, Radha K. Dhiman, Shyam Aggarwal, Seema Alam, Pradeep Bhaumik, Vinod K. Dixit, Ashish Goel, Bhabadev Goswami, Ashok Kumar, Manoj Kumar, Kaushal Madan, Natarajan Murugan, Aabha Nagral, Amarender S. Puri, Padaki N. Rao, Neeraj Saraf, Vivek A. Saraswat, Sanjeev Sehgal, Praveen Sharma, Koticherry T. Shenoy, Manav Wadhawan. INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids. Journal of Clinical and Experimental Hepatology 2018; 8(4): 403 doi: 10.1016/j.jceh.2018.06.010
|
| 16 |
Xue-Dong Zhang, Xue-Dong Song, Jian-Hua Lu, Yan Dai, Bin Li, Ping Zhu, Er-Hei Dai, Calvin Q. Pan, Wei Chen. Comparison of Autolumo A2000 Plus and Architect i2000 for detection of hepatitis B virus serological markers. Heliyon 2024; 10(14): e32698 doi: 10.1016/j.heliyon.2024.e32698
|
| 17 |
Martina Vitrone, Domenico Iossa, Luca Rinaldi, Pia Clara Pafundi, Rosa Molaro, Antonio Parrella, Roberto Andini, Enrico Ragone, Ciro Maiello, Rosa Zampino, Emanuele Durante-Mangoni. Hepatitis B virus reactivation after heart transplant: Incidence and clinical impact. Journal of Clinical Virology 2017; 96: 54 doi: 10.1016/j.jcv.2017.09.011
|
| 18 |
Yu-Hung Wang, Ja-Der Liang, Wang-Huei Sheng, Feng-Ming Tien, Chien-Yuan Chen, Hwei-Fang Tien. Hepatitis B reactivation during treatment of tyrosine kinase inhibitors—Experience in 142 adult patients with chronic myeloid leukemia. Leukemia Research 2019; 81: 95 doi: 10.1016/j.leukres.2019.05.001
|
| 19 |
Hyun Jae Kim, Seonkyung Lee, Yu Jin Koo, Eunjin Kwon, Hyo-Jung Kim, Jeong-Yoon Choi, Ji-Soo Kim. Tacrolimus for Treating Orbital and Cranial Form of Idiopathic Inflammatory Pseudotumors. Journal of Clinical Neurology 2020; 16(4): 674 doi: 10.3988/jcn.2020.16.4.674
|
| 20 |
Lan-Ying He, Yu-Lan Wang, Xu Tian, Wei-Qing Chen. The association of hepatitis B virus screening and antiviral prophylaxis with adverse liver outcomes in Chinese cancer patients undergoing chemotherapy. Medicine 2020; 99(14): e19647 doi: 10.1097/MD.0000000000019647
|
| 21 |
Catarina Meng, Carolina Belino, Luciano Pereira, Ana Pinho, Susana Sampaio, Isabel Tavares, Manuela Bustorff, António Sarmento, Manuel Pestana. Reactivation of Hepatitis B virus in kidney transplant recipients with previous clinically resolved infection: A single-center experience. Nefrología (English Edition) 2018; 38(5): 545 doi: 10.1016/j.nefroe.2018.02.013
|
| 22 |
Eimear Kitt, Molly Hayes, Ana María Cárdenas, Abby M. Green. Interpretation and management of positive anti‐hepatitis B core antibody tests in immunocompromised pediatric patients. Transplant Infectious Disease 2019; 21(3) doi: 10.1111/tid.13074
|
| 23 |
Soo-Kyung Park, Chang Hwan Choi, Jaeyoung Chun, Heeyoung Lee, Eun Sun Kim, Jae Jun Park, Chan Hyuk Park, Bo-In Lee, Yunho Jung, Dong-Il Park, Do Young Kim, Hana Park, Yoon Tae Jeen. Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases. Intestinal Research 2020; 18(1): 18 doi: 10.5217/ir.2019.09155
|
| 24 |
Wei Huang, Lingyao Du, Hong Tang. Hepatitis B Virus Reactivation: Overview and Management. Future Virology 2021; 16(12): 821 doi: 10.2217/fvl-2021-0275
|
| 25 |
UEG Week 2018 Poster Presentations. United European Gastroenterology Journal 2018; 6(S8) doi: 10.1177/2050640618792819
|
| 26 |
Matthew Kelling, Lubomir Sokol, Samir Dalia. Hepatitis B Reactivation in the Treatment of Non-Hodgkin Lymphoma. Cancer Control 2018; 25(1) doi: 10.1177/1073274818767879
|
| 27 |
Catarina Meng, Carolina Belino, Luciano Pereira, Ana Pinho, Susana Sampaio, Isabel Tavares, Manuela Bustorff, António Sarmento, Manuel Pestana. Reactivation of Hepatitis B virus in kidney transplant recipients with previous clinically resolved infection: A single-center experience. Nefrología 2018; 38(5): 545 doi: 10.1016/j.nefro.2018.02.004
|
| 28 |
Kyo Izumida, Atsushi Kaneko, Kazuya Takahashi, Shigeru Kusumoto, Tomoko Narita, Akiyoshi Takami, Shinsuke Iida, Katsumi Aoyagi, Yasuhito Tanaka. Clinical evaluation of a novel and highly sensitive immunoassay for anti‐hepatitis B core antigen using a fully automated immunochemical analyzer. Hepatology Research 2018; 48(13): 1081 doi: 10.1111/hepr.13229
|
| 29 |
Karima Abounouh, Ahd Ouladlahsen, Haya Altawalah, Ali A. Rabaan, Hind Dehbi, Fadila Guessous, Sayeh Ezzikouri. Advances in Antiviral Research. Livestock Diseases and Management 2024; : 393 doi: 10.1007/978-981-99-9195-2_16
|
| 30 |
Martin Feuchtenberger, Arne Schäfer, Axel Philipp Nigg, Michael Rupert Kraus. Hepatitis B Serology in Patients with Rheumatic Diseases. The Open Rheumatology Journal 2016; 10(1): 39 doi: 10.2174/1874312901610010039
|
| 31 |
Apostolos Koffas, Grace E Dolman, Patrick TF Kennedy. Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians. Clinical Medicine 2018; 18(3): 212 doi: 10.7861/clinmedicine.18-3-212
|
| 32 |
Arif Kılçar, Atalay Doğru. Evaluation of Hepatitis Serology Screening Frequency and Viral Reactivation in Patients Followed with Biological Therapy or Cytotoxic Chemotherapy. SDÜ Tıp Fakültesi Dergisi 2024; doi: 10.17343/sdutfd.1412752
|
| 33 |
Rashed Abdelaal, Beshoy Yanny, Mohamed El Kabany. HBV/HCV Coinfection in the Era of HCV-DAAs. Clinics in Liver Disease 2019; 23(3): 463 doi: 10.1016/j.cld.2019.04.003
|
| 34 |
Stefano Piaserico, Francesco Messina, Francesco Paolo Russo. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. American Journal of Clinical Dermatology 2019; 20(6): 829 doi: 10.1007/s40257-019-00457-3
|
| 35 |
Hidetaka Matsuda, Katsushi Hiramatsu, Yu Akazawa, Takuto Nosaka, Yasushi Saito, Yoshihiko Ozaki, Ryoko Hayama, Kazuto Takahashi, Tatsushi Naito, Kazuya Ofuji, Masahiro Ohtani, Tomoyuki Nemoto, Yukio Hida, Hideki Kimura, Yoshihiro Soya, Yasunari Nakamoto. Genetic polymorphism and decreased expression of HLA class II DP genes are associated with HBV reactivation in patients treated with immunomodulatory agents. Journal of Medical Virology 2018; 90(4): 712 doi: 10.1002/jmv.25011
|
| 36 |
J. Steuart Richards, Sharon Dowell, Mercedes Quinones. Comorbidity in Rheumatic Diseases. 2017; : 345 doi: 10.1007/978-3-319-59963-2_17
|
| 37 |
Aida Siyahian, Saad Ullah Malik, Adeela Mushtaq, Carol L. Howe, Aneela Majeed, Tirdad Zangeneh, Samar Iftikhar, Shahid Habib, Umar Zahid, Irbaz Bin Riaz, Zabih Warraich, Warda Faridi, Faiz Anwer. Prophylaxis for Hepatitis B Virus Reactivation after Allogeneic Stem Cell Transplantation in the Era of Drug Resistance and Newer Antivirals: A Systematic Review and Meta-Analysis. Biology of Blood and Marrow Transplantation 2018; 24(7): 1483 doi: 10.1016/j.bbmt.2018.02.027
|
| 38 |
Davide Fiore Bavaro, Deborah Fiordelisi, Gioacchino Angarano, Laura Monno, Annalisa Saracino. Targeted therapies for autoimmune/idiopathic nonmalignant diseases: risk and management of opportunistic infections. Expert Opinion on Drug Safety 2020; 19(7): 817 doi: 10.1080/14740338.2020.1767585
|
| 39 |
Joyce Wing Yan Mak, Alvin Wing Hin Law, Kimmy Wan Tung Law, Rita Ho, Carmen Ka Man Cheung, Man Fai Law. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era. World Journal of Gastroenterology 2023; 29(33): 4942-4961 doi: 10.3748/wjg.v29.i33.4942
Abstract(551) |
Core Tip(661) |
Full Article(HTML)(4776)
|
Full Article with Cover (PDF)-1470K(117)
|
Full Article (Word)-297K(54)
|
Audio-484K(5)
|
Peer-Review Report-212K(53)
|
Answering Reviewers-115K(64)
|
Supplementary Material-55K(73)
|
Full Article (PDF)-720K(403)
|
Full Article (XML)-468K(58)
|
Times Cited (12)
|
Total Visits (8570)
|
Open
|
| 40 |
Xing Cao, Yafei Wang, Panyun Li, Wei Huang, Xiaojuan Lu, Hongda Lu. HBV Reactivation During the Treatment of Non-Hodgkin Lymphoma and Management Strategies. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.685706
|
| 41 |
Yuqin Song, Hervé Tilly, Shinya Rai, Huilai Zhang, Jie Jin, Hideki Goto, Yasuhito Terui, Ho-Jin Shin, Won Seog Kim, Junning Cao, Jifeng Feng, Hyeon Seok Eom, Tae Min Kim, Xavier Cheng-Hong Tsai, Jyh-Pyng Gau, Hideo Koh, Liling Zhang, Yongping Song, Yu Yang, Wei Li, He Huang, Kiyoshi Ando, Jeff P. Sharman, Laurie H. Sehn, Lilian Bu, Xin Wang, Yanwen Jiang, Jamie Hirata, Calvin Lee, Jun Zhu, Koji Izutsu. Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial. Blood 2023; 141(16): 1971 doi: 10.1182/blood.2022017734
|
| 42 |
Marius Rademaker, Karen Agnew, Nicholas Anagnostou, Megan Andrews, Katherine Armour, Christopher Baker, Peter Foley, Kurt Gebauer, Monisha Gupta, Gillian Marshman, Diana Rubel, John Sullivan, Li‐Chuen Wong. Psoriasis and infection. A clinical practice narrative. Australasian Journal of Dermatology 2019; 60(2): 91 doi: 10.1111/ajd.12895
|
| 43 |
KASL clinical practice guidelines for management of chronic hepatitis B. Clinical and Molecular Hepatology 2019; 25(2): 93 doi: 10.3350/cmh.2019.1002
|
| 44 |
Alberto Enrico Maraolo, Ivan Gentile, Antonio Riccardo Buonomo, Biagio Pinchera, Guglielmo Borgia. Current evidence on the management of hepatitis B in pregnancy. World Journal of Hepatology 2018; 10(9): 585-594 doi: 10.4254/wjh.v10.i9.585
|
| 45 |
Yachao Tao, Dongbo Wu, Lingyun Zhou, Enqiang Chen, Changhai Liu, Xiaoqiong Tang, Wei Jiang, Ning Han, Hong Li, Hong Tang. Hepatitis B Virus Infection. Advances in Experimental Medicine and Biology 2020; 1179: 137 doi: 10.1007/978-981-13-9151-4_6
|
| 46 |
María Buti, María L. Manzano, Rosa M. Morillas, Montserrat García-Retortillo, Leticia Martín, Martín Prieto, María L. Gutiérrez, Emilio Suárez, Mariano Gómez Rubio, Javier López, Pilar Castillo, Manuel Rodríguez, José M. Zozaya, Miguel A. Simón, Luis E. Morano, José L. Calleja, María Yébenes, Rafael Esteban, Vincent Wong. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. PLOS ONE 2017; 12(9): e0184550 doi: 10.1371/journal.pone.0184550
|
| 47 |
Shigeru Kusumoto, Luca Arcaini, Xiaonan Hong, Jie Jin, Won Seog Kim, Yok Lam Kwong, Marion G. Peters, Yasuhito Tanaka, Andrew D. Zelenetz, Hiroshi Kuriki, Günter Fingerle-Rowson, Tina Nielsen, Eisuke Ueda, Hanna Piper-Lepoutre, Gila Sellam, Kensei Tobinai. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood 2019; 133(2): 137 doi: 10.1182/blood-2018-04-848044
|
| 48 |
G. Tapia Rico, M.M. Chan, K.F. Loo. The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B/C, HIV): A review of the available evidence. Cancer Treatment Reviews 2020; 86: 102011 doi: 10.1016/j.ctrv.2020.102011
|
| 49 |
Reem A. Shalabi, Michelle A. Worst, Thomas E. Hughes, Tracey Walsh‐Chocolaad, Lisa Cook, Kristen Gunn, Brian Wells, Rodica Ciurea, Georg Aue, Xin Tian, Richard W. Childs. Haematopoietic stem cell transplant patients have a high initial failure rate to hepatitis B vaccination that can be overcome with subsequent vaccination series. British Journal of Haematology 2022; 196(6): 1404 doi: 10.1111/bjh.17991
|
| 50 |
A. Marrone, N. Capoluongo, C. D'Amore, M. Pisaturo, M. Esposito, S. Guastafierro, I. Siniscalchi, M. Macera, A. Boemio, L. Onorato, L. Rinaldi, C. Minichini, L. E. Adinolfi, E. Sagnelli, L. Mastrullo, N. Coppola. Eighteen‐month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy. Journal of Viral Hepatitis 2018; 25(2): 198 doi: 10.1111/jvh.12802
|
| 51 |
Ahmad AlEnizi, Khaled AlSaeid, Adel Alawadhi, Eiman Hasan, Entesar H. Husain, Ahmad AlFadhli, Aqeel Ghanem, Fatemah Abutiban, Yaser Ali, Adeeba Al-Herz, Khuloud Mohammed, Waleed Alkandari, Ali Aldei, Hebah Alhajeri, Ahmad Dehrab, Sawsan Hayat. Kuwait Recommendations on Vaccine Use in People with Inflammatory Rheumatic Diseases. International Journal of Rheumatology 2018; 2018: 1 doi: 10.1155/2018/5217461
|
| 52 |
KASL clinical practice guidelines for management of chronic hepatitis B. Clinical and Molecular Hepatology 2022; 28(2): 276 doi: 10.3350/cmh.2022.0084
|
| 53 |
G. V. Volynets, A. I. Khavkin. Co-infection with hepatitis B and C viruses: current state of the problem. Experimental and Clinical Gastroenterology 2024; (1): 67 doi: 10.31146/1682-8658-ecg-221-1-67-74
|
| 54 |
Beshoy T. Yanny, Nyan L. Latt, Sammy Saab, Steven Han, Gina Choi, Jason Kramer, Amandeep K. Sahota. Risk of Hepatitis B Virus Reactivation Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection. Journal of Clinical Gastroenterology 2018; 52(10): 908 doi: 10.1097/MCG.0000000000000986
|